



ASX Announcement

6 November 2023

BCAL FILES FURTHER FOUNDATIONAL PATENT APPLICATION

BCAL Diagnostics Limited (ASX: BDX) (BCAL or Company), an Australian-based biotechnology company developing a blood test for breast cancer, today announced the filing of a further provisional patent application, Australian Provisional Patent Application No. 2023903491, covering additional lipid biomarkers detected in BCAL's revolutionary breast cancer diagnostic.

In line with BCAL's commitment to securing its intellectual property, the filing of this patent application expands the scope of BCAL's pending patent estate to cover additional lipid biomarkers that will supplement those covered in its foundational patent filings.

Following continued, rigorous statistical and experimental investigation into the particular lipid biomarkers that distinguish cancer patients from healthy subjects, BCAL has identified a number of new, additional lipid biomarkers that will complement BCAL's breast cancer diagnostic test. This new patent application covers these additional lipid biomarkers and their application in BCAL's first-in-class lipid-based breast cancer test.

This patent application is based on the analysis in BCAL's laboratory of the lipids found in plasma from new and larger breast cancer patient cohorts. Each patient's lipid profile has been interrogated and BCAL's analysis of the aggregate results has revealed a further subset of specific lipids that demonstrate important diagnostic power. Based on its laboratory analysis, BCAL is adapting its platform technology to allow the detection of the additional lipid biomarkers covered in this patent application and thereby drive improved diagnostic outcomes in breast cancer patients.

This new patent application will underpin future global patent filings covering these additional diagnostic lipid biomarkers in breast cancer diagnostics. While the final version of BREASTEST™ is expected to contain a subset of all lipids identified to have diagnostic utility, widening our patent cover provides both flexibility in test design and stronger protection from potential competition.

BCAL Executive Chair, Jayne Shaw, commented: *"Our cutting-edge analytics combined with expert clinical insight have revealed additional biomarkers that can supplement the diagnostic power created by our original technology. This new patent filing demonstrates the commitment BCAL has to protecting its proprietary technology. It builds on BCAL's foundational IP and protects this latest advance."*

BCAL CEO, Dr John Hurrell, commented: *"This is an important step in strengthening patent protection around the company's core diagnostic technology. This new filing builds on our earlier patent family and an existing portfolio of in-licensed IP, which protects the earlier work performed by BCAL's team in developing a diagnostic platform based on lipid signatures that are typical of patients with breast cancer. With our greater understanding of the lipid profiles involved, we believe we are well placed to develop an urgently needed, first-in-class diagnostic test for breast cancer."*

This announcement has been approved for release to the ASX by the Board.

ENDS

Jayne Shaw

Executive Chair

Jshaw@bcaldiagnostics.com

John Hurrell

Chief Executive Officer

jhurrell@bcaldiagnostics.com

ABOUT BCAL DIAGNOSTICS

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% specificity and 85% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>